NEPHROPLUS

Nephrocare Health Services Ltd.

NSE: NEPHROPLUS

BSE: 544647

Sector: Healthcare

Industry Group: Healthcare Services

Industry: Healthcare Service Provider

671.95-3.0 (-0.44%)

3 Jul, 3:30 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

84.4 / 100

Value Score

9.0 / 100

Price Momentum Score

61.1 / 100

QVM Score

49.8 / 100

Key Metrics

Market Cap

6772.52

P/E (TTM)

88.14

P/B

6.07

P/S (TTM)

6.78

EV/EBITDA

28.17

CAPE (5Y)

ROE (TTM)

9.04

ROCE (TTM)

13.37

ROA (TTM)

6.23

Avg 3Y ROE

10.41

Earnings 3Y CAGR

Sales 3Y CAGR

31.70

Sales 5Y CAGR

Debt/Equity

0.07

Consensus TP

680.00

Strong Buy %

0.00

Promoter Holding

63.85

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Nephrocare Health Services Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 32.16% for 12-month ended 31 Mar 2026 and the growth was 18.6 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 13.56

Value 32.16

-97.35238.8

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 21.13% for 12-month ended 31 Mar 2026 and the growth was 19.99 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low and declining Debt to Equity

The company has low Debt to Equity of 0.07 as on 31 Mar 2026 and Debt to Equity decreased by 0.37 in the last 1 year

What is Debt to Equity?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 88.14 indicates that the stock is expensive on a standalone basis and is at a 218.08% premium to industry median P/E

What is P/E Ratio?

Median: 27.71

Value 88.14

6.282638.46

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -15.0% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Not enough data

Low and declining ROE

The company reported low ROE of 9.04% for 12-month ended 31 Mar 2026 and ROE declined by -440 bps from 1 year ago

What is ROE (FY)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Moderate and stable operating margin

The company reported moderate operating margin of 13.65% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 100 bps from 1 year ago

What is Operating profit margin?

Company's earnings are of moderate quality

Earnings quality score of 64.5 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

64.5 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Nephrocare Health Services Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Nephrocare Health Services Ltd. Shareholding Pattern

Quarterly breakdown of Nephrocare Health Services Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2025	Dec 2025	Mar 2026
Total Promoter	-	63.85	63.85
Indian Promoter	-	21.07	21.07
Foreign Promoter	-	42.78	42.78
Institutions	-	12.27	18.59
Mutual Funds / UTI	-	3.44	3.17
FI/Bank/Insurance	0.00	1.55	1.50
Govt	-	-	-
FII	0.00	3.59	9.94
Other Institutions	0.00	3.69	3.97
Non-Institution	-	23.88	17.56
Bodies Corporate	-	0.23	0.69
Others (incl. Retail) No. of shareholders	0.00 0	23.65 2,12,845	16.87 43,206

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Nephrocare Health Services Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	17 Dec 2025	buy	₹ 490.00	5.70 lac	₹ 27.93 cr
MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	17 Dec 2025	sell	₹ 483.30	5.70 lac	₹ 27.55 cr
MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED	17 Dec 2025	buy	₹ 482.75	5.34 lac	₹ 25.78 cr
MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED	17 Dec 2025	sell	₹ 477.65	4.89 lac	₹ 23.36 cr
POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUND	17 Dec 2025	buy	₹ 481.77	34.28 lac	₹ 165.14 cr
POONAWALLA VISION FUND I	17 Dec 2025	buy	₹ 490.05	6.10 lac	₹ 29.89 cr
RAJASTHAN GLOBAL SECURITIES PVT LTD	17 Dec 2025	buy	₹ 491.00	50.00 k	₹ 2.46 cr
RAJASTHAN GLOBAL SECURITIES PVT LTD	17 Dec 2025	sell	₹ 490.10	5.20 lac	₹ 25.50 cr

No corporate action data available.

Company Profile

Overview of Nephrocare Health Services Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Nephrocare Health Services Limited, formerly Nephrocare Health Services Pvt Ltd, is an India-based company. The Company is primarily engaged in the business of providing dialysis and sale of related healthcare services and products. The Company offers comprehensive dialysis care through the network ...

Key personnel

Rohit Singh

Group Chief Executive Officer

Prashant Vinodkumar Goenka

Chief Financial Officer, Chief Risk Officer

Mr. Kishore Kathri

Company Secretary, Compliance Officer

Mr. Vikram VuppalaD

Executive Chairman, Managing Director

Mr. Vishal Vijay GuptaD

Non-Executive Nominee Director

Mr. Gaurav SharmaD

Non-Executive Nominee Director

Mr. Sunil Kumar ThakurD

Additional Non-Executive Nominee Director

Om Prakash ManchandaD

Independent Director

View all

Incorporated on

18 Dec 2009

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

17 Dec 2025

Free Float

4,54,28,271

Website

https://nephroplus.com/

Phone no.

+914042408039

Address

5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, HYDERABAD, 500081, India

Frequently Asked Questions

What is the current share price of Nephrocare Health Services Ltd.?

The current share price of Nephrocare Health Services Ltd. is ₹ 671.95 as of 3 Jul 2026.

What is the market capitalisation of Nephrocare Health Services Ltd.?

The market capitalisation of Nephrocare Health Services Ltd. stands at ₹ 6,772.52 Cr.

What is the PE ratio of Nephrocare Health Services Ltd.?

The Price-to-Earnings (PE) ratio of Nephrocare Health Services Ltd. is 88.14 as of the latest trailing twelve months data.

What is the ROE and ROCE of Nephrocare Health Services Ltd.?

Nephrocare Health Services Ltd. has a Return on Equity (ROE) of 9.04% and a Return on Capital Employed (ROCE) of 13.37% as per the latest financial reports.

What is the 52-week high and low of Nephrocare Health Services Ltd.?

The 52-week high of Nephrocare Health Services Ltd. is - and the 52-week low is -.

What is the dividend yield of Nephrocare Health Services Ltd.?

The dividend yield of Nephrocare Health Services Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Nephrocare Health Services Ltd.?

Foreign Institutional Investors (FII) hold 9.94%, Domestic Institutional Investors (DII) hold 4.67% and retail/public investors hold 16.87% of Nephrocare Health Services Ltd. shares.

What sector does Nephrocare Health Services Ltd. belong to?

Nephrocare Health Services Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Nephrocare Health Services Ltd. with a consensus target price of ₹ 680.00, implying 0.75% upside from current levels.

What is the beta of Nephrocare Health Services Ltd.?

The beta of Nephrocare Health Services Ltd. is -, indicating its price volatility relative to the broader market.

What is the RSI of Nephrocare Health Services Ltd.?

The 14-day Relative Strength Index (RSI) of Nephrocare Health Services Ltd. is 50.25, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Nephrocare Health Services Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Nephrocare Health Services Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile